Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day

a systematic review and economic evaluation

J Hislop, Z Quayyum, A Elders, C Fraser, D Jenkinson, G Mowatt, P Sharma, L Vale, R Petty

Research output: Contribution to journalArticle

6 Citations (Scopus)
4 Downloads (Pure)

Abstract

Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown.
Original languageEnglish
Pages (from-to)1-178
Number of pages178
JournalHealth Technology Assessment
Volume15
Issue number25
DOIs
Publication statusPublished - 2011

Fingerprint

Gastrointestinal Stromal Tumors
Cost-Benefit Analysis
sunitinib
Imatinib Mesylate

Cite this

@article{8a015860943a41859600b38868afb5bd,
title = "Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation",
abstract = "Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown.",
author = "J Hislop and Z Quayyum and A Elders and C Fraser and D Jenkinson and G Mowatt and P Sharma and L Vale and R Petty",
year = "2011",
doi = "10.3310/hta15250",
language = "English",
volume = "15",
pages = "1--178",
journal = "Health Technology Assessment",
issn = "1366-5278",
publisher = "National Co-ordinating Centre for HTA",
number = "25",

}

TY - JOUR

T1 - Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day

T2 - a systematic review and economic evaluation

AU - Hislop, J

AU - Quayyum, Z

AU - Elders, A

AU - Fraser, C

AU - Jenkinson, D

AU - Mowatt, G

AU - Sharma, P

AU - Vale, L

AU - Petty, R

PY - 2011

Y1 - 2011

N2 - Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown.

AB - Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown.

U2 - 10.3310/hta15250

DO - 10.3310/hta15250

M3 - Article

VL - 15

SP - 1

EP - 178

JO - Health Technology Assessment

JF - Health Technology Assessment

SN - 1366-5278

IS - 25

ER -